Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If it takes twenty years to build a ship, and the end goal is to build a ship, what accomplishments come into question at any time before the end goal is met? It's just business as usual until the the ship is built. Then you have your accomplishment. If at the end of the ship-building the ship does not float, then your position will have merit. But not until then.
I'n feeling good about our little biotech's chances of success, this round. At some point, the hurdles will have finally been cleared and we'll get the results most of us are aiming for. After all of these years and never being stronger in the game than we are now, not to mention as well staffed and affiliated as we are now, I'm thinking this could be the time. I'm looking forward to the next piece of news. I suspect it's going to be one of several big releases that bring this whole thing to fruition. Fingers crossed.
I think I understand your position. Perhaps mine is differentiated by the fact that I'm less concerned with the crusade and more concerned with share price. If it were to go up a 1000% on absolutely no basis whatsoever, I'd celebrate my earnings and walk past the complaint line whistling. So, to me, I suppose anything that counters negative movement is welcome, whether it's justified in some people's minds or not. I'll suggest that there's certainly nothing bad coming out of the idea of more buyers, unless someone simply doesn't like the company and/or its executives, or they're in a short position that's not paying out.
Spikes are short lived, otherwise they'd be trends. It seems there were some sellers at that range, which is no surprise given the fact that it's a stock in a market that travels both ways. Great observation.
There's nothing artificial about a stock having a little bounce back after being in oversold territory. This is completely organic movement.
At this level, we're engulfing the last three days' range of trading. A good signal, imo. There's been something going on lately. Hopefully, it will reveal itself soon.
So what does it mean? It's pretty cut and dried, the way I see it. The trading of PMCB shares has been banned in British Columbia as a result of a reporting issue in 2011. Now, with the updated reports being submitted, shares of PMCB may once again be traded in BC. The fiscal translation is small, but not negligible. Basically, This province of Canada will provide mostly buyers over the near-term future, likely resulting in a contribution to the health of the share price. My personal translation is that for reasons unknown to us, Mr. Wagonner has been motivated to free up this part of the market for trading. That very well could mean he's been receiving pressure to remediate the issue from potential investors, or it could mean a new subcontractor is coming aboard and they need a way to cash their check, if you catch my drift. I don't know if either of these scenarios is the case, but I can see an uptick in volume and a hike in PPS resulting, none-the-less.
Sure did, I posted it. I expect we'll start to see an uptick in volume over the coming months.
We're officially able to trade again in BC!
PharmaCyte Issues Corporate Overview and History
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--November 16, 2017--
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R) , today announced that it is providing a summary overview, corporate history and status report to address a regulatory compliance request from the British Columbia Securities Commission (BCSC) which, as of November 10, 2017, revoked the cease trade order involving PharmaCyte's securities.
In 2011, the BCSC ordered that all trading in the securities of Nuvilex, Inc. (now PharmaCyte Biotech, Inc.) cease in British Columbia until PharmaCyte filed the required records that would allow the BCSC to revoke the cease trade order. PharmaCyte recently applied to the BCSC to revoke the cease trade order. That order has now been revoked, allowing securities of PharmaCyte to once again be traded in British Columbia.
As required by the BCSC, PharmaCyte provides a corporate overview and a summary of its corporate history below.
Corporate Overview
PharmaCyte is a clinical stage biotechnology company focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as "Cell-in-a-Box(R) ." The Cell-in-a-Box(R) technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed.
PharmaCyte is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. PharmaCyte is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes based upon the encapsulation of a human cell line genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body using the Company's Cell-in-a-Box(R) technology. In addition, the Company is examining ways to exploit the benefits of the Cell-in-a-Box(R) technology to develop therapies for cancer based upon the constituents of the Cannabis plant, known as "cannabinoids."
Corporate History
PharmaCyte is a Nevada corporation incorporated in 1996. In 2013, PharmaCyte restructured its operations in an effort to focus on biotechnology, having been a nutraceutical products company before then. The restructuring resulted in PharmaCyte focusing all of its efforts upon the development of a unique, effective and safe way to treat cancer and diabetes. On January 6, 2015, the company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to better reflect the nature of its business.
As discussed above, presently, the company is a clinical stage biotechnology company focused on developing and preparing to commercialize therapies for cancer and diabetes using its proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box(R) . This resulted from entering into several important agreements.
On May 26, 2011, the Company entered into an Asset Purchase Agreement ("SG Austria APA") with SG Austria to purchase 100% of the assets and liabilities of SG Austria. As a result, Austrianova and Bio Blue Bird AG ("Bio Blue Bird"), then wholly owned subsidiaries of SG Austria, were to become wholly owned subsidiaries of PharmaCyte on the condition that PharmaCyte pay SG Austria US$2.5 million and 100,000,000 shares of PharmaCyte's common stock. PharmaCyte was to receive 100,000 shares of common stock of Austrianova and nine bearer shares of Bio Blue Bird representing 100% of the ownership of Bio Blue Bird.
Through two addenda to the SG Austria APA, the closing date of the SG Austria APA was extended twice by agreement between the parties.
In June 2013, PharmaCyte and SG Austria entered into a Third Addendum to the SG Austria APA ("Third Addendum"). The Third Addendum materially changed the transaction contemplated by the SG Austria APA. Under the Third Addendum, PharmaCyte acquired 100% of the equity interests in Bio Blue Bird and received a 14.5% equity interest in SG Austria. In addition, PharmaCyte received nine bearer shares of Bio Blue Bird to reflect its 100% ownership of Bio Blue Bird. PharmaCyte paid: (i) US$500,000 to retire all outstanding debt of Bio Blue Bird; and (ii) US$1.0 million to SG Austria. PharmaCyte also paid SG Austria US$1,572,193 in exchange for the 14.5% equity interest of SG Austria. The transaction required SG Austria to return to PharmaCyte the 100,000,000 shares of common stock held by SG Austria and for PharmaCyte to return to SG Austria the 100,000 shares of common stock of Austrianova then-held by PharmaCyte.
Effective as of the same date PharmaCyte entered into the Third Addendum, PharmaCyte and SG Austria entered into a Clarification Agreement to the Third Addendum ("Clarification Agreement") to clarify and include certain language that was inadvertently left out of the Third Addendum. Among other things, the Clarification Agreement confirmed that the Third Addendum granted PharmaCyte an exclusive, worldwide license to use, with a right to sublicense, the Cell-in-a-Box(R) technology for the development of treatments for cancer and use of Austrianova's Cell-in-a-Box(R) trademark and its associated technology.
Bio Blue Bird licensed certain types of genetically modified human cells ("Cells") from Bavarian Nordic A/S ("Bavarian Nordic") and GSF-Forschungszentrum für Umwelt u. Gesundheit GmbH (collectively, "Bavarian Nordic/GSF") pursuant to a License Agreement ("Bavarian Nordic/GSF License Agreement") to develop a therapy for cancer using encapsulated Cells. The licensed rights to the Cells pertain to the countries in which Bavarian Nordic/GSF obtained patent protection. Hence, facilitated by the acquisition of Bio Blue Bird, the Third Addendum provides PharmaCyte with an exclusive, worldwide license to use the Cell-in-a-Box(R) technology and trademark for the development of a therapy for cancer using the Cells.
In June 2013, PharmaCyte entered into the Diabetes License Agreement. PharmaCyte paid Austrianova US$2.0 million to secure this license.
In October 2014, PharmaCyte entered into the Melligen Cell License Agreement. PharmaCyte is in the process of developing a therapy for diabetes by encapsulating the Melligen cells using the Cell-in-a-Box(R) technology.
In December 2014, PharmaCyte entered into the Cannabis Licensing Agreement. PharmaCyte paid Austrianova US$2.0 million to secure this license. PharmaCyte is in the process of developing therapies for cancer and its symptoms through genetically engineered cells designed to activate cannabinoid molecules that have been encapsulated using the Cell-in-a-Box(R) technology.
In July 2016, PharmaCyte entered into a Binding Memorandum of Understanding with Austrianova ("Austrianova MOU"). Pursuant to the Austrianova MOU, Austrianova will actively work to seek an investment partner or partners who will finance clinical trials and further develop products for the therapies for cancer, in exchange for which PharmaCyte, Austrianova and any future investment partner or partners will each receive a share of the net revenue of applicable products.
In October 2016, the parties amended the Bavarian Nordic/GSF License Agreement to include the right to import, reflect ownership and notification of improvements, clarify which provisions survive expiration or termination of the Bavarian Nordic/GSF License Agreement, to provide rights to Bio Blue Bird to the clinical data after expiration of the licensed patent rights and to change the notice address and recipients of Bio Blue Bird.
In August 2017, PharmaCyte entered into a Binding Term Sheet with SG Austria and Austrianova pursuant to which the parties reached an agreement to amend certain provisions in the APA, the Diabetes Licensing Agreement and the Cannabis Licensing Agreement.
For more detailed information regarding PharmaCyte, readers are encouraged to read its disclosure filings made with the United States Securities and Exchange Commission available online at: (https://www.sec.gov/edgar/searchedgar/companysearch.html), including its most recent Form 10-K annual report filed on July 27, 2017, and Form 10-Q quarterly report filed on September 13, 2017.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as "Cell-in-a-Box(R) ." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
PharmaCyte's therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient's tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a "bio-artificial liver" and activate the chemotherapy drug at the site of the cancer. This "targeted chemotherapy" has proven effective and safe to use in past clinical trials and results in no treatment related side effects.
(MORE TO FOLLOW) Dow Jones Newswires
November 16, 2017 09:15 ET (14:15 GMT)
British Columbia Securities Commission Revokes -2-
PharmaCyte's therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box(R) technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a "bio-artificial pancreas" for purposes of insulin production.
Safe Harbor
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the United States Securities and Exchange Commission.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte's Investor Relations Department.
On behalf of
PharmaCyte Biotech, Inc.
/s/ Dr. Gerald W. Crabtree
View source version on businesswire.com: http://www.businesswire.com/news/home/20171116005374/en/
CONTACT: Investor Relations:
PharmaCyte Biotech, Inc.
Dr. Gerald W. Crabtree
Investor Relations Department
917.595.2856
Info@PharmaCyte.com
SOURCE: PharmaCyte Biotech, Inc.
Copyright Business Wire 2017
> Dow Jones Newswires
November 16, 2017 09:15 ET (14:15 GMT)
No sir. You've misinterpreted my suggestion. The company itself is not like building a house. The work it's undertaking is analogous to building a house. Most project-based work is the same. On a side note, I believe you meant 'oceanfront', since "beachfront" can be found on any inland lake.
I've always felt pre-market trading was irrational and difficult to read, so I discount it altogether unless it comes with substantial volume. What I find even more confusing is yesterday's price action. That being said, when I fail to understand something it usually amounts to nothing to be understood in the end, lol. I'm feeling pretty confident in this investment.
Fair assessment of time frame, I believe. If I'm not mistaken, Mr. Waggoner suggested a similar time frame in the conference call. One could argue that We've seen such time frames come and go, but just like building a house, it can go quick and easy or it can be laden with change orders, underachieving subcontractors, and zoning restrictions. For many people, it boils down to their own DD and their understanding and experience with such things. For others, it boils down to patience or trust. There is evidence of both camps on this message board.
I don't think there's any doubt people are buying and/or accumulating. I added 54% to my holdings a few days ago. Of course, I'm looking to better my position by averaging, which I typically wouldn't do. With the recent decline--unwarranted in magnitude--I believe new positions are being taken. The charts aren't telling me much yet, but I suspect we'll see a correction of sorts, and hopefully that will be followed by some news with substance.
PMCB is certainly not a biotech going bad, despite your wishes.
A lot of good this is doing me in my watchlist, lol. Congrats to the longs here.
Is anyone else confused by Citadel's level 2 reporting in the last two days?
I suppose I'm a little frustrated this morning with the share price. A few people get their patience tested and blow their load, and it opens the door for shorts and market makers to take advantage of downward pressure, exacerbating the move. Hopefully, they've made some money and they're done with PMCB for awhile.
I don't recall ever hearing good news come out of a lynching. Sometimes, you're better off waiting for the news to come to you.
It's nice to see nobody's twisting the company's arm for news anymore. smh
I see we have two buyers, actually.
It looks like something is afoot this morning.
You're right, others certainly have, lol. The PPS reflects that. I just wonder if it's more to do with vocalized sentiment than actual company communications. I hope somehow we both end up winners. Good luck.
But I was on the CC too. I heard everything you heard and I never flinched. Nor have others. The truth is, (and this is where I get deleted) neither of us knows how this is going to play out. You have your suspicions and I have mine. I suppose the biggest difference is that you find merit in warning investors about a future you're only speculating on, and I wouldn't feel confident in my ability to predict the future enough to sway another to either buy or sell. I'm kind of a soloist who does his own DD and plays his own cards. I've certainly been burned as you speak of. I took a bath to the tune of $30K on PWTC and several thousand on HRCT. That's the game when you play pennies. I don't fault you for selling, but I certainly don't want to be faulted for holding.
I might point out that market cap is unrelated to an entity's ability to have a technological breakthrough. I believe Steve Jobs did so from his garage. Pharmacyte is far better positioned to succeed than Steve was. I suppose time will reveal all.
It hasn't been easy or pleasurable going through this decline in share price, but I still can't sell knowing that the only thing pushing the price down is people who want the price down. Every negative comment I read is skewed just enough to appear valid. This technology isn't obsolete by any stretch of the imagination. If pancreatic cancer had a cure, then I'd say "Yeah, someone beat them to the punch." But that's not the case. Delays, sidesteps, and unforeseen challenges are par for the course. I've listened to the conference call in its entirety three times. I know everything everyone else knows. This decline is otherwise an anomaly. I'm going to continue holding, despite any further declines. Sure, I'll probably average down when we see a reversal, but not until then. Good luck all.
I think a more likely scenario is one in which the recent announcements would predispose the stock to selling pressure, lightening the impact of an oncoming XX-1 reverse split. From a business financial perspective, I would be contemplating and perhaps calculating my move in that regard. Lay your cards on the table in order to establish a post-selling base, then navigate a reverse split with increased sustainability, then leverage the newly established PPS to secure relationships/funding/deals (which are possibly already impending and contingent upon terms similar to those I'm speculating on). Follow that with news of substance. Done. That's precisely what I'd be thinking. It's not exactly all peaches and cream, but it's a sound alternative.
I should add that I have been seeing the likeliness of a reverse split for months now. I'm not one to fear such a thing, as it's only numbers being moved around. I don't care how many shares I own as long as the value is commensurate with my holdings. I suspect that the above mentioned scenario would enable the company to move forward and potentially yield gains in PPS. But that's still not the reason I hold my position. I hold my position because I can see the forest through the trees.
From a roll call perspective, I'm still in the game. I watched the panic selling with disappointment, but I knew better than to cut and run because I listened to every word during that conference call. Despite the nay-saying, I still see the bottom line as being potentially highly profitable. I don't really care about high and low swings on this one. It's just a buy and hold for me; a gamble, basically. I put my money in the overall science of PMCB, not any one individual. I thought Mr. Waggoner's announcements were somewhat discouraging from a timeline point-of-view, but I'm not a guy who needs everything here and now. I'm a guy who has a realistic disposition and it's not easily moved by things like fear and hype. That being said, I'm staying the course. I might have to watch the chart more closely and buy a dip or two to better average, but I'll still be here.
Why is that the question? Whether it's two cents or ten cents, it's still pennies. If it's three cents, it's three cents and nothing else. It's not like stocks just stay at one price; they go up and down. I don't share your analysis of future movement south. But if it turns out to do so, I'll probably have to eat my words and pony up for another chunk.
I really didn't think I would get filled at .053 this morning. That's my last block. Bring it.
Actually, thenewmixer, Google is unfamiliar with this image...
[url][/url][tag]https://www.google.com/search?tbs=sbi:AMhZZivnkN7EBKLTuNMcW1rxWQbV387WRdgM8J2wuhNOO4kuF3ytR_1j8VN-r37vAsmnDiyy_1J6dYWEvTmiQ-JZo2q29YECD8Ht36xmaJdlccfx4HGtLJHKGKflndfKRLWNVHTI8eWu1Hoi-vtyZaeDcVXWir9pQbDpkIE3whl5tMZwPFgacJnLUt_1Uezll3eo6NBQAsWRLp2vFffAhXOiWxTFcsunJJB1MnXT62qm3PUfKpDmpXYIiRRrQd8EpvG52bxucPbuaUlDYwcpmVX1LZWYmP3begMnWCV0KACDY39QrL_1YMfTtxkCFwdRLyE27479Q98ycP50E4rwtY_15VogZgIlHdHbpig&hl=en[/tag]
There's something truly satisfying about investor panic, lol. Since the advent of online trading platforms, the market wanes at the mercy of human emotion. SMH
Exactly my position.
I jumped in on the basing setup. I believe we're in for a nice run (or two, etc.).
I will agree that some posters on this board tend to conjure up some pretty wild ideas. Just because our new board member has connections in China doesn't mean the US market is suddenly devoid of potential. That's ridiculous sentiment. What it means is that we have a new board member with connections in China. Fifty thousand dollars in sitting compensation and a half million shares isn't going to suffice if this guy was a pivot point in the company's market targets. No, you're going to have to pony up a little better than that if you want to focus all of your efforts on an overseas market. He's another cog in the wheel, and a valuable cog I'm sure. I don't doubt PMCB's management; there's not a single merited concern I've read on this board, short of dilution and an eventual R/S. And even those are just bumps in the road. The truth is, concordia, that you really don't have any clue as to the level of contribution made by anyone in this company.
Thanks, SLAM. It's refreshing to read the words of another rational individual. I sometimes do get dragged into the mire as a result of my inherent desire to further understand individual behaviors. Unfortunately, a web browser and anonymity offer few dissection tools, lol. That being said, the bottom line remains; PMCB is an easy investment decision for me.
GLTYA,
Syz
Just because you don't have your answers doesn't mean the answers are bad by default. By "we", you must mean yourself. You can exclude me and many others from those statements. I happen to be confident in my investment, regardless of news frequency, because I have fortitude and a good mind for business. It has become crystal clear through the release of insignificant PR's that news without substance results in negative action in trading. I suspect the company saw the pattern. I see people crying and whining for news, and when PMCB tries to pat their backs the price drops. Then they cry and whine over the lack of newsworthy substance. And now a barrage of emails and phone calls to investor relations? It forces their hand to respond with crap news. Ridiculous. All because people are afraid of things that don't exist. Typical. It's a self-fulfilling prophesy that frustrates the heck out of confident investors like me.
I'm in.
I got a slow start this morning and was only able to pick up 5000 shares @ .530 :( Hell of a closing rally.
I took some losses elsewhere in order to double my holdings in PMCB yesterday morning. I haven't seen this much potential in a penny in about 12 years or so. I like damn near everything about it, and the one or two things I don't care for are always par for the course with pennies. I'm seeing the likeliness of a new trend through technicals, and I'm seeing very clearly that Pharmacyte Biotech, Inc. has its act together. I've held shares through some thin times over the last eight months, but I never saw a single red flag even though at times I wanted to. So I held. I think we're probably 4-6 weeks from anything concrete as far as news goes, but that's a quasi-informed estimate. Hopefully, we'll soon find out that certain cancerous presentations have met their match, and as a result those who stood fast with this investment will reap the benefits. Good luck to everyone making a play here, long or short.